urokinase

4-Chlorophenylguanidine hydrochloride 是一种有效的尿激酶选择性抑制剂。

ZK824190 是具有口服活性尿激酶型纤溶酶原激活剂 (uPA) 选择性抑制剂，对 uPA，tPA 和 Plasmin 的IC50分别为 237，1600 和 1850 nM。ZK824190在多发性硬化症中有研究价值。

Urokinase peptidolytic (Urokinase-type plasminogen activator) 是一种丝氨酸蛋白酶，是丝氨酸蛋白酶纤溶酶的一种非活性形式(酶原)。纤溶酶的激活可触发蛋白水解级联反应，进而参与血栓溶解或细胞外基质降解，涉及血管疾病和癌症相关研究。

Benzamidine hydrochloride (Benzamidine HCl) 是可逆的胰蛋白酶样丝氨酸蛋白酶 (trypsin-like serine proteases) 竞争性抑制剂，对 uPA、类胰蛋白酶、胰蛋白酶和 Xa 因子作用的Ki 分别为 97 µM、20 µM、21 µM 和 110 µM。

MK-1064 (Urokinase inhibitor 1) 是一种选择性食欲素 2 (2-SORA)受体拮抗剂，可用于失眠患者的研究。

SSR-182289A (Free) is a thrombin inhibitor.

4-Aminobenzamidine dihydrochloride (p-Aminobenzamidine dihydrochloride) 是一种强胰蛋白酶 (trypsin)抑制剂，也是一种相对较弱的尿激酶型纤溶酶原激活剂 (uPA) 抑制剂 (Ki=82 μM)。4-Aminobenzamidine 可抑制 SCID 小鼠体内前列腺肿瘤的生长。

6-Shogaol (6-Shogaol) 是从生姜中分离的一种天然产物，具有抗癌、抗炎和抗氧化的多种生物活性。

UKI-1 is a urokinase-type plasminogen activator system synthetic inhibitor.

Upamostat 是一种丝氨酸蛋白酶抑制剂，也是一种具有口服活性的 WX-UK1 前药，是一种尿激酶型纤溶酶原激活剂 (uPA) 抑制剂。

ZK824859 is an oral available and selective inhibitor of urokinase plasminogen activator (uPA)(IC50s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively).

ZK824859 hydrochloride is an oral available and selective inhibitor of urokinase plasminogen activator (uPA)(IC50s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively).

Upamostat，即Mesupron和WX-671，是一种口服生物利用度高的二代丝氨酸蛋白酶抑制剂前药，源于3-酰胺基苯丙氨酸，针对人体尿激酶原激活剂（uPA）系统，具有潜在的抗肿瘤和抗转移活性。口服给药后，丝氨酸蛋白酶抑制剂WX-671转化为活性形式Nα-(2,4,6-三异丙基苯基磺酰)-3酰胺基-(L)-苯基丙氨酸-4-乙氧基羰基哌嗪酰胺（WX-UK1），该物质能抑制多种丝氨酸蛋白酶，尤其是uPA。通过抑制uPA，可能进而抑制肿瘤生长和转移。

UK-371804 is a potent and selective urokinase-type plasmogen activator (uPA) inhibitor with excellent enzyme potency (Ki=10 nM) and selectivity profile (2700-fold versus plasmin and 4000-fold versus tPA).

BC 11 hydrobromide是一种选择性 TMPRSS2 和尿激酶 (uPA) 抑制剂 。BC-11 诱导线粒体活性减弱，促进活性氧的产生，促进细胞凋亡，可用于研究乳腺癌。

Angstrom6 (A-6 peptide) 是一种从单链尿激酶纤溶酶原激活剂(scuPA)中提取的 8 肽，它能干扰 uPA uPAR 级联反应并抑制下游效应。Angstrom6 具有抗肿瘤活性，能通过与 CD44 结合并调节 CD44 介导的细胞信号传导，抑制肿瘤细胞的迁移、侵袭和转移。

Chromozym U can be used as a chromogenic substrate test for urokinase in Shigella.

PKSI-527 is an inhibitor of plasma kallikrein (Ki = 0.81 μM). It is selective for plasma kallikrein over glandular kallikrein, plasmin, thrombin, urokinase, and Factor Xa (Kis = >500, 390, >500, 200, and >500 μM, respectively). PKSI-527 reduces bradykinin generation induced by kaolin and λ-carrageenan ex vivo in human plasma. It also prolongs partial thromboplastin and euglobulin clot lysis times. In vivo, PKSI-527 (300 mg/kg per day) reduces hyperplasia, pannus formation, and infiltration of inflammatory cells in the tarsal joint of mice with collagen-induced arthritis.

GGACK is an inhibitor of urokinase-type plasminogen activator (uPA) and factor Xa (Kis = 1.8 and 8.7 μM, respectively).1,2 1.Kettner, C., and Shaw, E.The susceptibility of urokinase to affinity labeling by peptides of arginine chloromethyl ketoneBiochim. Biophys. Acta569(1)31-40(1979) 2.Kettner, C., and Shaw, E.The selective affinity labeling of factor Xa by peptides of arginine chloromethyl ketoneThromb. Res.22(5-6)645-652(1981)

UK122 is a highly effective and specific inhibitor of urokinase-type plasminogen activator (uPA) with an IC50 value of 0.2 μM. It displays negligible to minimal inhibition towards tissue-type plasminogen activator (tPA), plasmin, thrombin, and trypsin (all IC50 >100 μM). Functioning as a 4-oxazolidinone analogue, UK122 is an anticancer agent that effectively inhibits cancer cell migration and invasion.

ZK824190 hydrochloride 是一种选择性的、口服具有活力的尿激酶型纤溶酶原激活剂 (uPA) 抑制剂，能够作用于 uPA (IC50: 237 nM)、tPA (IC50: 1600 nM) 和 Plasmin (IC50: 1850 nM)。ZK824190 hydrochloride 能够用于研究多发性硬化症的研究

ZK824859 hydrochloride 是一种选择性的、口服具有活力的尿激酶型纤溶酶原激活剂 (uPA) 抑制剂。ZK824859 hydrochloride 对人 uPA，tPA 和纤溶酶的 IC50 值分别为 79 nM，1580 nM 和 1330 nM。

CJ-463 is a potent ans selective uPA inhibitor. Treatment with CJ-463 resulted in a significant inhibition of primary tumor growth, with the highest efficacy seen in the 100 mg kg group. Urokinase (uPA) plays a crucial role in carcinogenesis by facilitating tumor cell invasion and metastasis. CJ-463 may be a novel agent for treatment of lung cancer.

UK-356,202 is a potent and selective urokinase-type plasminogen activator (Ki = 37 nM). Urokinase plasminogen activator (uPA, urokinase) is a trypsinlike serine protease and a therapeutical target for many cancer types, including breast, ovarian, and pancreatic cancer. uPA is a valuable oncology target.